Engineered human collagen-based products
Founded in 2004 by Laura Niklason, M.D., Ph.D. with Drs. Shannon Dahl and Juliana Blum, Humacyte is a privately-held company led by experts in clinical trials, regulatory affairs, business and commercial development, finance, and intellectual property management. Our headquarters in Morrisville, NC includes a dedicated clean facility for clinical production, and laboratories for cell isolation, analytical/QC, and product development.
Humacyte’s mission is to become the leading company in novel, off-the-shelf extracellular matrix tissue products, and especially those that could provide lifesaving improvements in treatments for vascular conditions. Because we grow these tissue replacements in vitro from banked vascular cells that are decellularized, our products do not require cells from the patient and can be easily stored until patients and their surgeons need them.
Humacyte names new president and CEO
RESEARCH TRIANGLE PARK – Humacyte, a biotech company focused on regenerative medicine, has named Jeffrey Lawson MD, Ph.D, president and CEO. Former CEO Carrie S. Cox assumes the role of executive chair.
The company landed a $75 million equity round in March and a $150 million equity investment from Fresenius Medical Care earlier this month.
Lawson has been involved in the development of Humacyte’s vascular technologies, in collaboration with his career-long research partner and Humacyte founder Dr. Laura Niklason, over the past 20 years. He has worked with Humacyte since its founding in 2004 to support the science, preclinical and clinical testing of Humacyte’s novel tissue engineered blood vessels, which are being developed for dialysis access and cardiovascular surgery.
Lawson was appointed chief medical officer of Humacyte in 2015 to oversee the clinical development of these vascular technologies as the company initiated Phase III clinical trials for dialysis access and expanded clinical programs in vascular repair and trauma.
Prior to joining Humacyte, Lawson served in leadership roles at Duke University Medical Center, including Professor of Surgery and Pathology, Vice Chair for Research in Surgery, and Director of Clinical Trials for the Department of Surgery.
Cox, as executive chair, will serve as a senior, strategic advisor to Dr. Lawson and the executive team, helping to develop ongoing strategy for Humacyte as the company works toward regulatory approval and commercialization for its flagship product, the investigational Human Acellular Vessel (HAV), HUMACYL.
Carrie Cox. Photo copyright Humacyte.
Durham’s Humacyte lands $150M from Fresenius Medical Care
According to the companies, the investment will see Fresenius (NYSE: FMS) take a 19 percent fully diluted ownership stake in Humacyte and obtain the exclusive global rights to commercialize Humacyte’s human acellular vessel Humacyl upon approval by certain health authorities.
“Humacyte is at this true inflection point in the development of our blood vessel,” says Humacyte Chief Medical Officer Dr. Jeff Lawson. Securing a partnership “with one of the most important, large corporations in this space [is critically important for] where we are right now as we plan the next 18 to 24 months toward commercialization,” he says.
A phase 3 trial of Humacyl in patients with end-stage renal disease has completed enrollment with data expected later this year. The product has the potential to become part of a person’s living tissue as well as last longer and produce fewer complications than synthetic vessels.